سعر Ranitidine 75mg eff. gr. in 6 sachets (cancelled) 2026

Ranitidine 75 mg effervescent granules, 6 sachets (Pharopharma, Egypt); listed as cancelled.

• Headache (sometimes severe); rarely malaise, dizziness, somnolence, insomnia, vertigo, reversible confusion or hallucinations (mainly in severely ill elderly); constipation, diarrhoea, nausea/vomiting, abdominal pain, rare pancreatitis.General active-ingredient information · DailyMed (US National Library of Medicine)
• Rare: hepatitis (discontinue immediately), arrhythmias (tachycardia, bradycardia, AV block), blood count changes including agranulocytosis and aplastic anaemia, rash/erythema multiforme, hypersensitivity reactions including anaphylaxis and angioedema, acute interstitial nephritis, gynaecomastia/galactorrhoea.General active-ingredient information · DailyMed (US National Library of Medicine)

• Hypersensitivity to ranitidine or any ingredient of the product.General active-ingredient information · DailyMed (US National Library of Medicine)

• Symptomatic response does not preclude gastric malignancy.General active-ingredient information · DailyMed (US National Library of Medicine)
• Ranitidine is excreted mainly by the kidney: adjust dose in renal impairment; use caution in hepatic dysfunction. Avoid in patients with a history of acute porphyria (may precipitate attacks).General active-ingredient information · DailyMed (US National Library of Medicine)
• False-positive urine protein tests with Multistix may occur; sulfosalicylic acid testing is recommended.General active-ingredient information · DailyMed (US National Library of Medicine)
• On 1 April 2020 the US FDA requested withdrawal of all prescription and OTC ranitidine products from the US market because the impurity NDMA (a probable human carcinogen) can increase over time and with storage above room temperature.General active-ingredient information · U.S. Food and Drug Administration (FDA)

• WarfarinAltered prothrombin time reported; monitor closely.DailyMed (US National Library of Medicine)
• ProcainamideHigh ranitidine doses reduce renal excretion of procainamide and N-acetylprocainamide; monitor for toxicity at oral ranitidine doses above 300 mg/day.DailyMed (US National Library of Medicine)
• Ketoconazole, atazanavir, delavirdine, gefitinibAbsorption may be reduced by increased gastric pH (ketoconazole exposure reduced up to 95% at gastric pH >= 6).DailyMed (US National Library of Medicine)
• Triazolam, midazolam, glipizideExposure may increase (oral midazolam up to 65%, triazolam about 30%, glipizide 34%); monitor.DailyMed (US National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; animal studies at up to 160 times the human dose showed no fetal harm. Use in pregnancy only if clearly needed.General active-ingredient information · DailyMed (US National Library of Medicine)
• Ranitidine is secreted in human milk; use caution in nursing mothers.General active-ingredient information · DailyMed (US National Library of Medicine)